These are notes on money-musical-chairs among drug companies. Big-time money.
Clues as to why there is such a tidal wave of cash:
One: Consolidation, of course. Fewer giant companies, who have greater control over the market, are too big to fail, and have more lobbying power with governments.
Two: The companies are making deals left and right to temporarily give stockholders and prospective investors the impression that “something good” is happening, while concealing the fact that numerous new drugs in the testing pipeline are failing to produce beneficial results, and are unsafe. Sleight of hand.
Three: The companies are making very favorable loan deals with banks, enabling them to buy out other drug firms. Before the loan repayments are completed, the companies will have sold themselves (and the debt) to bigger fish.
Source: News To Me